Drug intelligence / Profile preview

Iris Ace

Development stage
Unknown
Lead developer
Taisho Pharmaceutical
Modality
Small Molecules
Administration
Ophthalmic
01

Overview

Iris Ace is a multi-ingredient over-the-counter ophthalmic solution developed by Taisho Pharmaceutical, primarily indicated for the relief of eye fatigue, conjunctival congestion (redness), and blurred vision. The formulation utilizes a combination of active agents to address various symptoms of ocular strain: neostigmine methylsulfate acts as an acetylcholinesterase inhibitor to improve the eye's accommodative focus adjustment; tetrahydrozoline hydrochloride serves as an alpha-adrenergic agonist to constrict blood vessels and reduce redness; and chlorpheniramine maleate provides antihistaminic effects to alleviate itching and irritation. Additionally, the product contains metabolic support components such as taurine, potassium L-aspartate, and pyridoxine hydrochloride (Vitamin B6) to enhance tissue respiration and repair, alongside epsilon-aminocaproic acid which provides anti-inflammatory benefits. It is widely used in Japan to mitigate discomfort caused by prolonged digital screen use and environmental irritants.

Brand names
Iris AceIris Ace L
02

Targets

AcetylcholinesteraseADRA1A (α1A)PLG (Plasminogen)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on Iris Ace.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Iris Ace.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call